EGFR and neoplasm: Activation/overexpression of specific oncogenes, associated with cancer development and progression, such as KRAS, SMAD4 and EGFR,116 chemotherapy resistance genes, such as NRF2,117ABCB1, and MDR1,118 metabolism‐associated genes, such as hypoxia inducible factor 1α and GLUT‐1,119, 120 and stemness‐related genes, such as CD133, CD44, NANOG, CXCR4, CECAM5, and WNT,118 or silencing/deficiency/mutation of tumor suppressor genes, such as NF2,121PTEN,122 and adenomatous poliposis coli gene,123 can be targeted by the CRISPR/Cas9 gene editing system.